Skip to main content
SpringerLink
Log in

Recent Developments Regarding the Use of Monoamine Oxidase Inhibitors in Psychopharmacology

  • Chapter
Guidelines for the Use of Psychotropic Drugs

Abstract

The first effective antidepressant drugs were a series of inhibitors of monoamine oxidase (MAO) developed during the late 1950s. Their use was superceded by that of the tricyclic antidepressants, which appeared more generally effective and lacked the dangerous side effect of hypertensive crises. In the last few years, there Las been a spate of articles and editorials suggesting that the MAO-inhibiting drugs are underutilized, that there are subgroups of patients who respond preferentially to them, and that they are generally safe (Robinson et al., 1978; Editorial, 1976; Quitkin et al., 1979).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

  • Ananth, J.D., and Luchins, D. A review of combined tricyclic and MAOI therapy. Compr. Psychiatry 18: 221–230, 1977.

    Article  PubMed  CAS  Google Scholar 

  • Anthony, M., and Lance, J.W. Monoamine oxidase inhibition in treatment of migraine. Arch. Neurol. 21: 263–268, 1969.

    Article  PubMed  CAS  Google Scholar 

  • Aulakh, C.S., Cohen, R.M., Pradhan, S.N., and Murphy, D.L. Self-stimulation responses are altered following long-term but not short-term treatment with clorgyline. Brain Research, in press.

    Google Scholar 

  • Ayuso-Gutierrez, J.L., and Lopez-Iboralino, J.J. Tryptophan and an MAOI (Nialamide) in the treatment of depression. Int. Pharmacopsych. 6: 92–97, 1971.

    CAS  Google Scholar 

  • Banki, C.M. Cerebrospinal fluid amine metabolites after combined amitriptylinetriiodothyronine treatment of depressed women. Fur. J. Clin. Pharm. 11: 311–315, 1977.

    Article  CAS  Google Scholar 

  • Bartholomew, A. An evaluation of tranylcypromine in the treatment of depression. Med. J. Aust. 1: 655–662, 1962.

    Google Scholar 

  • Barton, J.L. Orgasmic inhibition by phenelzine. Am. J. Psychiatry 136: 1616–1617, 1979.

    PubMed  CAS  Google Scholar 

  • Beckmann, H., and Riederer, P. Monoamine Oxidase and Its Selective Inhibitors: New Concepts in Therapy and Research. Basel, Karger, 1983.

    Google Scholar 

  • Blackwell, B. Adverse effects of antidepressant drugs. Part 1: Monoamine oxidase inhibitors and tricyclics. Drugs 21: 201–219, 1981.

    Article  Google Scholar 

  • Brenner, R., and Shopsin, B. The use of monoamine oxidase inhibitors in schizophrenia. Biol. Psychiatry 15: 633–647, 1980.

    PubMed  CAS  Google Scholar 

  • British Medical Research Council. Clinical trial of the treatment of depressive illness. Br. Med. J. 1: 881–886, 1965.

    Article  Google Scholar 

  • Campbell, I.C., Murphy, D.L., Gallager, D.W., Tallman, J.F., and Marshall, E.F. Neurotransmitter-related adaptation in the central nervous system following chronic monoamine oxidase inhibition. In Singer, T.P., Von Korff, R.W., and Murphy, D.L., eds., Monoamine Oxidase: Structure, Function, and Altered Functions. New York, Academic Press, pp. 517–530, 1979a.

    Google Scholar 

  • Campbell, I.C., Robinson, D.S., Lovenberg, W., and Murphy, D.L. The effects of chronic regimens of clorgyline and pargyline on monoamine metabolism in the rat brain. J. Neurochem. 32: 49–55, 1979b.

    Article  PubMed  CAS  Google Scholar 

  • Campbell, I.C., Shiling, D.J., Lipper, S., Slater, S., and Murphy, D.L. A biochemical measure of monoamine oxidase type A and type B inhibitor effects in man. J. Psychiatry Res. 15: 77–84, 1979c.

    Article  CAS  Google Scholar 

  • Cawthon, R.M., Pintar, J.E., Haseltine, F.P., and Breakefield, X.O. Differences in the structure of A and B forms of human monoamine oxidase. J. Neurochem. 37: 363–372, 1981.

    Article  PubMed  CAS  Google Scholar 

  • Cohen, R.M., Campbell, I.C., Dauphin, M., et al. Changes in a-and ß-receptor densities in rat brain as a result of treatment with monoamine oxidase inhibiting antidepressants. Neuropharmacology 21: 293–298, 1982a.

    Article  PubMed  CAS  Google Scholar 

  • Cohen, R.M., Aulakh, C.S., Campbell, I.C., and Murphy, D.L. Functional subsensitivity of alpha 2 adrenoreceptors accompanying reductions in yohimbine binding after clorgyline treatment. Fur. J. Pharmacol., 81: 145–148, 1982b.

    CAS  Google Scholar 

  • Cohen, R.M., Pickar, D., Garnett, D., Lipper, S., Gillen, J.C., and Murphy, D.L. REM sleep suppression induced by selective monoamine oxidase inhibitors. Psychopharmacology 78: 137–140, 1982c.

    Article  PubMed  CAS  Google Scholar 

  • Coppen, S., Shaw, D.M., and Farrel, J.P. Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet 1: 79–80, 1963.

    Article  PubMed  CAS  Google Scholar 

  • Csanda, E., Antal, J., Anthony, M., and Csanaky, A. Experiences with 1-deprenyl in Parkinsonism. J. Neural Transm. 43: 263–269, 1978.

    Article  PubMed  CAS  Google Scholar 

  • Davidson, J., McLeod, M., Law-Yone, B., and Linnoila, M. A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline on refractory depression. Arch. Gen. Psychiatry 35: 639–642, 1978a.

    Article  PubMed  CAS  Google Scholar 

  • Davidson, J., McLeod, M.N., and White, H.L. Inhibition of platelet monoamine oxidase in depressed subjects treated with phenelzine. Am. J. Psychiatry 135: 470–472, 1978b.

    PubMed  CAS  Google Scholar 

  • Denney, R.M., Fritz, R.M., Patel, N.T., and Abell, C.W. Human liver MAO-A and MAO-B separated by immunoaffinity chromatography with MAO-B-specific monoclonal antibody. Science 215: 1400–1403, 1982.

    Article  PubMed  CAS  Google Scholar 

  • Diamond, M.A., Murray, R.H., and Schmid, D.G. Idiopathic postural hypotension: Physiologic observations and report of a new mode of therapy. J. Clin. Invest. 49: 1341–1348, 1970.

    Article  PubMed  CAS  Google Scholar 

  • Editorial. New look at monoamine oxidase inhibitors. Br. Med. J. 2: 69, 1976.

    Google Scholar 

  • Eisler, T., Teravainen, H., Nelson, R., Knebs, H., Weise, V., Lake, C.R., Ebert, M.H., Whetzel, N., Murphy, D.L., Kopin, I.J., and Caine, D.B. Deprenyl in Parkinson disease. Neurology 3 1: 19–23, 1981.

    Google Scholar 

  • Elsworth, J.D., Glover, V., Reynolds, G.P., Sandler, M., Lees, A.J., Phuapradit, P., Shaw, K.M., Stern, G.M., and Kumar, P. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the “cheese effect.” Psychopharmaeology 57: 33–38, 1978.

    Article  CAS  Google Scholar 

  • Fowler, C.J., Callingham, B.A., Mantle, T.J., and Tipton, K.F. Monoamine oxidase A and B: A useful concept ? Biochem. Pharmacol. 27: 97–101, 1978.

    Article  CAS  Google Scholar 

  • Giller, E., and Loeb, J. MAO inhibitors and platelet MAO inhibition. Commun. Psychopharmacol. 4: 79–82, 1980.

    PubMed  CAS  Google Scholar 

  • Giller, E., Bialos, D., Riddle, M., Sholomskas, A., and Harkness, L. Monoamine oxidase inhibitor-responsive depression. Psychiatry Res. 6: 41–48, 1982.

    Article  PubMed  CAS  Google Scholar 

  • Glassman, A.H., and Platman, S.R. Potentiation of a monoamine oxidase inhibitor by tryptophan. J. Psych. Res. 7: 83–88, 1969.

    Article  CAS  Google Scholar 

  • Himmelhoch, J.M., Defre, T., Kupfer, D.J., Swartzburg, M., and Byck, R. Treatment of previously intractable depression with tranylcypromine and lithium. J. Nerv. Ment. Dis. 155: 216–220, 1972.

    Article  PubMed  CAS  Google Scholar 

  • Hough, L.B., and Domino, E.F. Tele-methylhistamine oxidation by type B monoamine oxidase. J. Pharmacol. Exp. Ther. 208: 422–428, 1979.

    PubMed  CAS  Google Scholar 

  • Insel, T.R., Murphy, D.L., Cohen, R.M., Alterman, I., Kilts, C., and Linnoila, M. Obsessive-compulsive disorder: A double-blind trial of clomipramine and clorgyline. Arch. Gen. Psychiatry (in press).

    Google Scholar 

  • Isberg, R.A. A comparison of phenelzine and imipramine in an obsessive-compulsive patient. Am. J. Psychiatry 139: 1250–1251, 1981.

    Google Scholar 

  • Jeneke, M.A. Rapid response of severe obsessive-compulsive disorder to tranylcypromine. Am. J. Psychiatry 138: 1249–1250, 1981.

    Google Scholar 

  • Kellar, K.T., Cascio, C.S., and Butler, T.A. Differential effects of electroconvulsive shock and antidepressant drugs on serotonin-2-receptors in rat brain. Eur. J. Pharmacol. 69: 515–518, 1981.

    Article  PubMed  CAS  Google Scholar 

  • Kenney, W.C., Nagy, J., Salach, J.I., and Singer, T.P. In T.P. Singer, R.W. Von Korff, and D.L. Murphy, eds., Monoamine Oxidase: Structure, Functions, and Altered Functions, New York, Academic Press, 1979, pp. 25–38.

    Google Scholar 

  • Knoll, J. The pharmacology of selective MAO inhibitors. ln M.B.H. Youdim, and E.S. Paykel, eds. Monoamine Oxidase Inhibitors: The State of the Art. New York, John Wiley and Sons Ltd., 1981, pp. 45–61.

    Google Scholar 

  • Kupfer, D.J., and Detre, T.P. Tricyclic and monoamine-oxidase-inhibitor antidepressants: Clinical use. In L.L. Iversen, S.D. Iversen, and S.H. Snyder, eds., Handbook of Psychopharmacology. Affective Disorders: Drug Actions in Animals and Man, vol. 14, New York, Plenum Press, 1978, pp. 199–232.

    Google Scholar 

  • Lees, A.J., Shaw, K.M., Kohout, L.J., Stern, G.M., Elsworth, J.D., Sandler, M., and Youdim, M.B.H. Deprenyl in Parkinson’s disease. Lancet 2: 791–795, 1977.

    Article  PubMed  CAS  Google Scholar 

  • Lipper, S., Murphy, D.L., Slater, S., and Buchsbaum, M.S. Comparative behavioral effects of clorgyline and pargyline in man: A preliminary evaluation. Psychopharmacology 62 (2): 123–128, 1979.

    Article  PubMed  CAS  Google Scholar 

  • Lipsedge, J.S., Haijjoff, J., Huggins, P., Napier, L., Pearce, J., Pine, D.F., and Rich, M. The management of severe agoraphobia: A comparison of iproniazid and systematic desensitization. Psychopharmacologia 32: 67–80, 1973.

    Article  PubMed  CAS  Google Scholar 

  • Major, L.F., Murphy, D.L., Lipper, S., and Gordon, E. Effects of clorgyline and pargyline on deaminated metabolites of norepinephrine, dopamine and serotonin in human cerebrospinal fluid. J. Neurochem. 32: 229–231, 1979.

    Article  PubMed  CAS  Google Scholar 

  • Major, L.F., Lake, R.C., Lipper, S., Lerner, P., and Murphy, D.L. The central noradrenergic system and affective response to MAO inhibitors. Frog. Neuro-Psychopharmacol. 3: 5–6, 1980.

    Google Scholar 

  • Maycock, A.L., Abeles, R.H., Salach, J.I., and Singer, T.P. The structure of the covalent adduct formed by the interaction of 3-dimethy-amino-l-propyne and the flavine of mitochondrial amine oxidase. Biochemistry 15: 114–125, 1976.

    Article  PubMed  CAS  Google Scholar 

  • Moises, H.-W., and Beckmann, H. Antidepressant efficacy of tranylcypromine isomers: A controlled study. J. Neural Transm. 50: 185–192, 1981.

    Article  PubMed  CAS  Google Scholar 

  • Murphy, D.L. The behavioral toxicity of monoamine oxidase inhibiting antidepressants. Adv. Pharmacol. Chemother. 14: 71–105, 1977.

    Article  PubMed  CAS  Google Scholar 

  • Murphy, D.L. Substrate-selective monoamine oxidases: Inhibitor, tissue, species and functional differences. Biochem. Pharmacol. 27: 1889–1893, 1978.

    Article  PubMed  CAS  Google Scholar 

  • Murphy, D.L., Lipper, S., Slater, S., and Shiling, D. Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man. Psychopharmacology 62 (2): 129–132, 1979.

    Article  PubMed  CAS  Google Scholar 

  • Murphy, D.L., Pickar, D., Jimerson, D., Cohen, R.M., Garrick, N.A., Karoum, F., and Wyatt, R.J. Biochemical indices of the effects of selective MAO inhibitors (clorgyline, pargyline and deprenyl) in man. In E. Usdin, S. Dahl, L.F. Gram, and O. Lingjaerde, eds., Clinical Pharmacology in Psychiatry, London, MacMillan Press, 198la, pp. 307–316.

    Google Scholar 

  • Murphy, D.L., Roy, B., Pickar, D., Lipper, S., Cohen, R.M., Jimerson, D., Lake, C.R., Muscettola, G., Saavedra, J., and Kopin, I.J. Cardiovascular changes accompanying monoamine oxidase inhibition in man. In E. Usdin, N. Weiner, and C. Creveling, eds., Function and Regulation of Monoamine Enzymes: Basic and Clinical Aspects. London, MacMillan, 198lb, pp. 549–560.

    Google Scholar 

  • Murphy, D.L., Cohen, R.M., Garrick, N.A., Siever, L.J., and Campbell, I.C. Utilization of substrate selective monoamine oxidase inhibitors to explore neurotransmitter hypotheses of the affective disorders. In R.M. Post, and J.C. Ballenger, eds., Neurobiology of the Mood Disorders. Baltimore, Williams and Wilkins Co., in pressa.

    Google Scholar 

  • Murphy, D.L., Cohen, R.M., Siever, L.J., Roy, B., Karoum, F., Wyatt, R.J., Garrick, N.A., and Linnoila, M. Clinical and laboratory studies with selective monoamine oxidase inhibiting drugs: Implications for hypothesized neurotransmitter changes associated with depression and antidepressant drug effects. In H. Beckmann and P. Riederer, Monoamine Oxidase and Its Selective Inhibitors: New Concepts in Therapy and Research. Karger, Basel, 1983, pp. 287–303.

    Google Scholar 

  • Nanda, R.N., Johnson, R.H., and Keogh, H.J. Treatment of neurogenic orthostatic hypotension with a monoamine oxidase inhibitor and tyramine. Lancet 2: 1164–1167, 1976.

    Article  PubMed  CAS  Google Scholar 

  • Nelson, D.L., Herbet, A., Glowinski, J., and Hamon, M. [3H]Harmaline as a specific ligand of MAO A-II. Measurement of the turnover rates of MAO A during ontogenesis in the rat brain. J. Neurochem. 32: 1829–1836, 1979.

    Article  PubMed  CAS  Google Scholar 

  • Olpe, H.-R., and Schellenberg, A. Reduced sensitivity of neurons to noradrenaline after chronic treatment with antidepressant drugs. Bur. J. Pharmacol. 63: 7–13, 1980.

    Article  CAS  Google Scholar 

  • Olpe, H.-R. Differential effects of clomipramine and clorgyline on the sensitivity of cortical neurons to serotonin: Effect of chronic treatment. Bur. J. Pharmco. 69: 375–377, 1981.

    Google Scholar 

  • Paech, C., Salach, J.I., and Singer, T.P. In T.P. Singer, R.W. Von Korff, and D.L. Murphy, eds., Monoamine Oxidase: Structure, Functions, and Altered Functions, New York, Academic Press, 1979, pp. 39–50.

    Google Scholar 

  • Paykel, E.S., Parker, R.R., Penrose, R.J.J., and Rassaby, E.R. Depressive classification and prediction of response to phenelzine. Br. J. Psychiatry 134: 572–581, 1979.

    Article  PubMed  CAS  Google Scholar 

  • Peroutka, S., and Snyder, S.H. Long-term antidepressant treatment decreases spiroperidol labeled serotonin receptor binding. Science 210: 88–90, 1980.

    Article  PubMed  CAS  Google Scholar 

  • Pickar, D., Cohen, R.M., Jimerson, D.C., Lake, R.L., and Murphy, D.L. Tyramine infusions and selective MAO inhibitor treatment. II. Interrelationships among pressor sensitivity changes, platelet MAO inhibition and plasma MHPG reduction. Psychopharmacology 74: 8–12, 1981.

    Article  PubMed  CAS  Google Scholar 

  • Pickar, D., Murphy, D.L., Cohen, R.M., Campbell, I.C., and Lipper, S. Behavioral disturbances during the administration of selective and nonselective MAO inhibitors to depressed patients. Arch. Gen. Psychiatry, 39: 535–548, 1982.

    Article  PubMed  CAS  Google Scholar 

  • Pletscher, A., Gey, F.K., and Burkand, W.P. Inhibitors of monoamine oxidase and decarboxylase of aromatic amino acids. In Handbook of Experimental Pharmacology 19: 593–735, 1966.

    CAS  Google Scholar 

  • Ponto, L.B., Perry, P.J., Liskow, B.I., and Seaba, H.H. Drug therapy reviews: Tricyclic antidepressant and monoamine oxidase inhibitor combination therapy. Am. J. Hosp. Pharm. 34: 954–961, 1977.

    PubMed  CAS  Google Scholar 

  • Potter, W.Z., Murphy, D.L., Wehr, T.A., Linnoila, M., and Goodwin, F.K. Clorgyline: A new treatment for refractory rapid cycling patients. Arch. Gen. Psychiatry, 1982.

    Google Scholar 

  • Quitkin, F., Rifkin, A., and Klein, D.F. Monoamine oxidase inhibitors. A review of antidepressant effectiveness. Arch. Gen. Psychiatry 36: 749–760, 1979.

    Article  PubMed  CAS  Google Scholar 

  • Raskin, A. Adverse reactions to phenelzine: Results of a nine-hospital depression study. J. Clin. Pharmacol. 12: 22–25, 1972.

    CAS  Google Scholar 

  • Ravaris, C.L., Robinson, D.S., Ives, J.O., Nies, A., and Bartlett, D. Phenelzine and amitriptyline in the treatment of depression. Arch. Gen. Psychiatry 37: 1075–1080, 1980.

    Article  PubMed  CAS  Google Scholar 

  • Reynolds, G.P., Rausch, W.D. and Riederer, P. Effects of tranylcypromine stereo-isomers on monoamine oxidation in man. Br. J. Clin. Pharmacol. 9: 521–523, 1980.

    PubMed  CAS  Google Scholar 

  • Robinson, D.S., Nies, A., Ravaris, L. and Lamborn, K.R. The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive-anxiety states. Arch. Gen. Psychiatry 29: 407–413, 1973.

    Article  PubMed  CAS  Google Scholar 

  • Robinson, D.S., Nies, A., Ravaris, C.L. Ives, J.O., and Bartlett, D. Clinical pharmacology of phenelzine. Arch. Gen. Psychiatry 35: 629–635, 1978.

    Article  PubMed  CAS  Google Scholar 

  • Robinson, D.S., Nies, A., Ravaris, C.L., Ives, J.O., and Bartlett, D. Clinical Psychopharmacology of phenelzine: MAO activity and clinical response. In Lipton, M.A., DiMascio, A., and Killam, K.F., eds., Psychopharmacology: A Generation of Progress, New York, Raven Press, 1978, pp. 961–973.

    Google Scholar 

  • Robinson, D.S., Nies, A. and Cooper, T.B. Relationships of plasma phenelzine levels to platelet MAO inhibition, acetylator phenotype, and clinical outcome in depressed outpatients. Clin. Pharmacol. Ther. 29: 180, 1980.

    Google Scholar 

  • Rowan, P.R., Paykel, E.S., Parkert, R.R., Gatehouse, J.M., and Rao, B.M. Tricyclic anti-depressant and MAO inhibitor: Are there different effects7t In M.B.H. Youdim and E.S. Paykel, eds., Monoamine Oxidase Inhibitors-The State of the Art, New York, John Wiley and Sons, 1981, pp. 125–140.

    Google Scholar 

  • Sallinger-Barnette, M.M., Mendels, J., and Frazer, A. The effect of psychoactive drugs on beta-adrenergic receptor binding sites in rat brain. Seuropharmacology 19: 447–454, 1980.

    Article  Google Scholar 

  • Sargant, W. Drugs in the treatment of depression. Br. Med. J. 1: 225–227, 1961.

    Article  PubMed  CAS  Google Scholar 

  • Savage, D.J., Mendels, J., and Frazer, A. Monoamine oxidase inhibitors and serotonin uptake inhibitors: Differential effects on [3H] serotonin binding sites in rat brain. J. Pharmacol. Exp. Ther. 212: 259–263, 1980.

    PubMed  CAS  Google Scholar 

  • Schacter, M., Price, P.A. and Parkes, J.D. Deprenyl in narcolepsy. Lancet 1: 831–832, 1979.

    Article  Google Scholar 

  • Schacter, M., Marsden, C.D., Parkes, J.D., Jenner, P., and Testa, B. Deprenyl in the management of response fluctuations in patients with Parkinson’s disease on levodopa. J. Neurol. Neurosurg. Psychiatry 43: 1016–1021, 1980.

    Article  Google Scholar 

  • Sheehan, D.V., Ballenger, J., and Jacobsen, G. Treatment of endogenous anxiety with phobic, hysterical, and hypochrondriacal symptoms. Arch. Gen. Psychiatry 37: 51–59, 1980.

    Article  PubMed  CAS  Google Scholar 

  • Siever, L.J., Cohen, R.M., and Murphy, D.L. Antidepressants and az-adrenergic autoreceptor desensitization. Am. J. Psychiatry 138: 681–682, 1981.

    PubMed  CAS  Google Scholar 

  • Simpson, L.L., and Cabot, B. Monoamine oxidase inhibitors. In Simpson, L.L., ed., Drug Treatment of Mental Disorders. New York, Raven Press, pp. 147–160, 1976.

    Google Scholar 

  • Singer, T.P., Von Korff, R.W., and Murphy, D.L. Monoamine Oxidase: Structure, Function and Altered Functions, New York, Academic Press, 1979.

    Google Scholar 

  • Solyom, L., Hesseltine, G.F.D., McClure, D.J., Solyom, C., Led-Widge, B., and Steinberg, G. Behavior therapy versus drug therapy in the treatment of phobic neuroses. Can. Psych. Assoc. J. 18: 25–32, 1973.

    CAS  Google Scholar 

  • Squires, R.F. Monoamine oxidase inhibitors: Animal pharmacology. In L.L. Iversen, S.D. Iversen, and S.H. Snyder, eds., Handbook of Psychopharmacology, Affective Disorders: Drugs Actions in Animals and Man, vol. 14, New York, Plenum Press, 1978, pp. 1–58.

    Google Scholar 

  • Stockley, I.H. Monoamine oxidase inhibitors. Part I: Interactions with sympathomimetic amines. Pharmaceutical J. 210: 590–594, 1973a.

    CAS  Google Scholar 

  • Stockley, I.H. Monoamine oxidase inhibitors. Part 2: Interactions with anti-hypertensive agents, hypoglycaemics, CNS depressants, narcotics and antiParkinsonian agents. Pharmaceutical J. 210: 95–98, 1973b.

    Google Scholar 

  • Sulser, F., Vetulani, J., and Mobley, P. Mode of action of antidepressant drugs. Biochem. Pharmcol. 27: 257–261, 1978.

    Article  CAS  Google Scholar 

  • Tyrer, P., Candy, J., and Kelly, D. Phenelzine in phobic anxiety: A controlled trial. Psycho. Med. 3: 120–124, 1973.

    Article  CAS  Google Scholar 

  • Tyrer, P., Gardner, M., Lambourn, J., and Whitford, M. Clinical and pharmacokinetic factors affecting response to phenelzine. Br. J. Psychiatry 136: 359–365, 1980.

    Article  PubMed  CAS  Google Scholar 

  • White, K., Pistole, T., and Boud, J.L. Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study. Am. J. Psychiatry 137: 1422–1425, 1980.

    PubMed  CAS  Google Scholar 

  • White, K., and Simpson, G. Combined MAOI-tricyclic antidepressant treatment: A reevaluation. J. Clin. Psychopharm. 1: 264–282, 1981.

    Article  CAS  Google Scholar 

  • Wyatt, R.J., Fram, D.A., Buchbinder, R., and Snyder, F. Treatment of intractable narcolepsy with a monoamine oxidase inhibitor. N. Engl. J. Med. 285: 987–991, 1971.

    Article  PubMed  CAS  Google Scholar 

  • Yates, C.M., and Loudon, J.B. Acetylator status and inhibition of platelet monoamine oxidase following treatment with phenelzine. Psychol. Med. 9: 777–779, 1979.

    Article  PubMed  CAS  Google Scholar 

  • Youdim, M.B.H., and Paykel, E.S. Monoamine Oxidase Inhibitors. The State of the Art. New York, John Wiley and Sons, 1981.

    Google Scholar 

  • Young, J.P.R., Lader, M.H., and Hughes, W.C. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment on depressed outpatients. Br. Med. J. 2: 1315–1317, 1979.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Dennis L. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laurence B. Guttmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert M. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Clarke Institute of Psychiatry, University of Toronto, Canada

    Harvey C. Stancer Ph.D., M.D., F.R.C.P.(C)  & Vivian M. Rakoff M.A., M.B., F.R.C.P.(C)  & 

  2. Toronto General Hospital, University of Toronto, Canada

    Paul E. Garfinkel M.S., M.D., F.R.C.P.(C)

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Spectrum Publications, Inc.

About this chapter

Cite this chapter

Murphy, D.L., Guttmacher, L.B., Cohen, R.M. (1984). Recent Developments Regarding the Use of Monoamine Oxidase Inhibitors in Psychopharmacology. In: Stancer, H.C., Garfinkel, P.E., Rakoff, V.M. (eds) Guidelines for the Use of Psychotropic Drugs. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-7618-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-7618-7_5

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-011-7620-0

  • Online ISBN: 978-94-011-7618-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation